Abstract Primary headache is a common malady that is often under-recognized and frequently inadequately managed in spite of the fact that it affects up to 95 % of the population in a lifetime. Many forms of headache, including episodic tension and migraine headaches, if properly diagnosed, are reasonably amenable to treatment, but a smaller, though not insignificant, percent of the population suffer daily from a chronic, intractable form of headache that destroys one's productivity and quality of life. These patients are frequently seen in neurological practices at a point when treatment options are limited and largely ineffective. In the following review, we will discuss mechanisms drawn from recent studies that address the transition from acute to chronic pain that may apply to the transformation from episodic to chronic daily headaches which may offer opportunities for preempting headache transformation.
Introduction
Pain in the head is often referred to by patients and physicians by the general term Bheadache^regardless of the origin of the pain. Head pain is a common, disruptive, and often debilitating condition that affects up to 95 % of individuals at some time in their life [1] [2] [3] . Some headaches may be related to an identifiable underlying syndrome or inciting cause. These secondary headaches should be treated as in other areas of the body by addressing the underlying cause. Conversely, head pain may arise spontaneously, unrelated to any known cause, antecedent event or condition and be the defining feature of the malady. The latter types of head pain comprise the primary headaches which occur in many forms. The most prominent forms of primary headache include migraine, and tension-type and cluster headaches. In terms of severity, tension-type headaches tend to be irritating and often self limited, whereas migraine and cluster are life-long conditions and are generally more debilitating. When headaches in any form become chronic, they are more difficult to diagnose and more difficult to treat. Here, we will discuss mechanisms that have been proposed to play a role in the transition from acute to chronic pain in other regions of the body that may also act in the transformation of episodic to chronic daily headaches and how knowledge of these mechanisms may help in the prevention and future management of these difficult headaches.
threshold and the summation of potentially modifiable, internal, and external environmental and conditional factors such as e.g., hormones, foods, irritants, stress, obesity, fatigue, that when presented in a temporally overlapping fashion triggers a headache [4] . Once the headache threshold is reached, control is best achieved if treatment is initiated early in the evolution of the headache by prudently administering abortive measures to limit the intensity and duration of an individual headache episode [5] . As with many acute pain conditions, the episodic forms of primary headache are responsive to abortive treatment with physical and cognitive modalities, e.g., physical therapy, yoga, massage, meditation, improved sleep hygiene, acupuncture, and biofeedback [6••] or the as-needed administration of mild analgesic medications, e.g., aspirin, acetaminophen, and non-steroidal anti-inflammatory drugs (NSAIDs) [7] . Occasional interventional procedures, e.g., nerve blocks, trigger point and botulinum toxin injections, have been employed in spite of the lack of evidence-based support [8] [9] [10] . More specific treatments including ergotamine and triptan formulations have been identified and approved by the Food and Drug Administration (FDA) specifically for the treatment of migraine headache. If the headache threshold is high and the abortive treatments are effective, episodic headache occurrences tend to remain relatively mild and infrequent. However, if the treatments are only marginally effective or prolonged and the headache threshold is low, there is a greater chance that the acute, episodic forms of headache will convert to a chronic daily and more complex form. The approach to management then is to prevent the development of chronicity by reducing the number of modifiable triggers, to select treatments that are less likely to produce complications on their own, and to consider the initiation of prophylactic therapy to decrease the frequency and the intensity of the headache episodes. Prophylactic treatments have included the use of tricyclic antidepressant medications [5, 6••, 11-14] , antiepileptic drugs [5, 6••, 14-20] , antihypertensive beta-blocking, calcium channel-blocking and angiotensin receptor-blocking agents [5, 14, [21] [22] [23] 24 •], antispasmodic medications [6••, 25] , and some over-the-counter vitamins, minerals, and supplements, e.g., Feverfew, Butterbur, magnesium, riboflavin, coenzyme Q10, and melatonin [26, 27] . Of these formulations, only propranolol, metoprolol, timolol, topiramate, and valproic acid have been approved for migraine prophylaxis. A previously approved medication, methysergide, is no longer available in the USA, likely due to its association with retroperitoneal/retropulmonary fibrosis. Although not all of the agents used in the abortive and prophylactic treatment of episodic headaches have been approved by the FDA or have only been approved for specific headache types, many of the medications have been found anecdotally to be beneficial for many patients in the management of several headache conditions. Although treatments both abortive and prophylactic are numerous and relatively effective, the patients' under-recognition of the dangers of missing the diagnosis often leads to an increase in the number of headache occurrences and prolonged attempts at self medication. This coupled with physicians' inability to properly diagnose headache and intervene appropriately further increases the likelihood of the transformation of an episodic to a more intractable, chronic condition.
Episodic to Chronic Transformation
Unfortunately, the chronic forms of primary headache tend to be refractory to both abortive and prophylactic treatment and are far more disabling [28] . The rapidity with which the transformation from episodic to chronic headache occurs varies and depends on many factors such as headache frequency and severity and on which treatments are employed to manage the pain [4, 29] . The prevalence of chronic daily headache (CDH) in the USA is 4.1 % per 13,000 [28] . The incidence is anywhere from 40-60 % of the population at any given time. These headaches occur often enough to be perceived as a daily occurrence, although patients can have periods of time with little or no headache. The diagnosis and treatment of CDH is difficult because in all its forms, CDH may or may not be associated with medication overuse, and, thus, the treatment of each headache type may differ even within the same designation. Ironically, the use of some of the most effective abortive analgesic medications themselves may be a major complicating factor [30] . Ergotamines, triptans, mixed barbiturate formulations, and opioids are often provided for the management of severe and frequent episodic headaches, but are particularly problematic because they tend to produce rebound or medication-overuse headaches (MOH), an extremely common secondary condition for which the underlying cause must be a primary focus for treatment [31, 32] . The mechanisms involved in the development of MOH are thought to involve the activation of toll-like receptor-4 on microglia and astrocytes that results in the release of proinflammatory mediators, analgesic tolerance, and consequent pain increase [33] [34] [35] [36] [37] . The recurrence of these events potentially leads to repetitive activation of peripheral afferents, increased serotonin levels, the increased release of calcitonin gene-related peptide (CGRP) [38] and glutamate [39] , and a decreased uptake of neurotransmitters. The presence of higher levels of glutamate in the synaptic cleft leads to the activation of N-methyl D-aspartate (NMDA) glutaminergic receptors resulting in an increase in intracellular calcium, the activation of calcium-calmodulin protein kinase II α (CaMKIIα), brainderived neurotrophic factor (BDNF), protein kinase A and C (PKA and PKC), and an increase in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutaminergic receptors that sets the stage for central sensitization, the strengthening of signal transmission and neuronal plasticity [30, 32, [40] [41] [42] [43] . The current approach to managing MOH is to discontinue the use of the offending abortive medications, but the potential utilization of agents such as monocyline [34, 44] , amitriptyline [45] , ibudilast [45] [46] [47] [48] , (+)-naltrexone [32] , and cannabinoids [49] [50] [51] as a means to control glial activation and TLR4 activity may warrant further investigation as potential treatment options to aid in managing MOH [36, 37, 52] .
CDH is divided into four groups: chronic migraine (CM), chronic tension-type headache (CTTH), hemicrania continua (HC), and new daily persistent headache (NDPH). Generally, all forms of CDH can initially present in an episodic form that later becomes chronic. NDPH may be the exception, but its similarity to tension-type headaches is suggestive of the possibility that these headaches are a form of transformed TTH that arose in the absence of a history of episodic headaches because the prior headaches were exceptionally mild and were either unnoticed or ignored when they occurred and were forgotten at the time the history was taken. Alternatively, it has been proposed that NDPH may be a form of secondary headache, in that cases have been reported in which the headaches were associated with post-viral, post-surgical, and postinfection syndromes [3, [53] [54] [55] [56] [57] [58] [59] [60] . Of the chronic primary headache forms, NDPH and HC are usually considered to initially present in the chronic condition whereas CM and CTTH typically progress from an episodic to a chronic condition. As noted earlier, medication overuse is not a prerequisite for developing CDH, but chronic headaches are often exacerbated by or occur in association with medication overuse, and in many instances, medication overuse can be similar in character and frequency to the primary CDH [32, 61••] . At this time, with the exception of onabotulinumtoxinA that is approved by the FDA only for the management of the CM form of CDH, specific treatments for managing CDH are relegated to the offlabel use of analgesics, botulinum toxin, and/or adjuvant medications used for treating epilepsy and chronic pain of nonmalignant origin [62] [63] [64] . Due to the difficulty in establishing a clear diagnosis and in distinguishing among the different CDHs and their relationship to confounding features, the treatment of all forms of CDH are generally the same.
Breaking the Cycle
The initiation of treatment involves several components that may be done sequentially or simultaneously. The first and most important step in the process is to discontinue the current regimen of analgesic medications. The withdrawal of analgesic medications can be done with or without the use of bridging medications depending upon the severity of the headaches and the patient's ability to tolerate the often extended process [61••, 65] . In approximately 77 % of CDH sufferers, discontinuation of the overused medication alone will result in the return to an episodic form of headache that can then be more easily managed [3] . The second component of managing chronic headache is the inclusion of non-pharmacologic treatments listed above for treating episodic headaches. The third is the initiation of a prophylactic medication regimen in an effort to reduce the frequency and intensity of both the chronic headaches and the acute exacerbations. This may be done during analgesic medication withdrawal, but the desired effect may not be optimally achieved until the analgesic withdrawal process is complete [66] . Finally, establish a plan to rotate abortive treatments for headaches that are likely to occur in spite of analgesic withdrawal and prophylaxis [61••] . The selection of medications should more effectively target the primary headache type, e.g., indomethacin for HC, be less likely to produce analgesic rebound or hyperalgesia, e.g., longacting NSAIDS or long-acting triptans, and be limited to periods of time that reduce the likelihood of overuse. The maintenance of a headache diary indicating the headache frequency and intensity, the quantity of abortive medications used, and the number of work absences or emergency room visits are helpful in documenting the success of the treatment plan.
Despite all best efforts, many CDHs remain refractory to current treatment methods. The reasons for resistance to treatment are unclear, but the features associated with the transformation of headache does not appear dissimilar to the events that occur in the transition from acute to chronic pain states that occur in other areas of the body [67] . It has often been observed that stimulus repetition, signal reinforcement, and the mechanisms underlying the maintenance and amplification of signal strength and its resulting dedicated response are reminiscent of the process involved in learning and the formation of memories that, once formed, are a permanent quality of the beholder [40, 68] . It has been postulated that general nociception and headache transformation may rely on mechanisms that are similar to those thought to subserve the formation of memory [43] like "long-term potentiation (LTP)" [69, 70] , neuronal plasticity [71] [72] [73] [74] , and a process called "hyperalgesic priming" [75] . Hyperalgesic priming is the process by which an injurious event produces changes in peripheral afferents that results in an exaggerated and prolonged hyperalgesic response to a subsequent minimally or nonnoxious stimulus and may have a more direct bearing on the transformation from acute to chronic pain states that develop in the head and other areas of the body.
The basic learning or priming mechanism generally follows the first phase of a Pavlovian pattern of classical conditioning; an unconditional stimulus produces a reflexive or unconditional response [76, 77] . The unconditional stimulus initiates a cascade of events that involves the release of serotonin, the presynaptic increase of intracellular calcium, the activation of cyclic adenosine monophosphate (cAMP), PKA, and PKC, and the reduction of potassium currents resulting in the increased release of excitatory neurotransmitter. The stronger and more frequent the unconditional stimulus, the greater the likelihood of activating post-synaptic NMDA receptors and voltage-gated calcium channels, thereby further increasing intracellular calcium, reducing potassium currents, amplifying AMPA receptors, and initiating immediate early genes for the transcription and translation of proteins to support the establishment of new connections [40] . Increased intracellular calcium also stimulates the production of nitric oxide and prostaglandins, through the activation of the inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) pathways to strengthen and reinforce the long-term potentiation of the unconditional response and sensitize adjacent neural circuitry through the release of nitric oxide and prostaglandins. Repetitive stimulation also leads to the activation of microglia and astrocytes that release pro-inflammatory cytokines that are responsible for the activation of PKC in isolectin B4-positive nociceptors and hyperalgesic priming [78] . Unfortunately, once learning has occurred, it is difficult, if not impossible to reverse. The more often an event is repeated, e.g., daily, the more difficult it becomes to manage. Clearly, the best option for managing CDH is to prevent their occurrence by mitigating the inducing triggers if possible and providing non-pharmacologic and prudent pharmacologic options for abortive management and prophylaxis. Because of potentially significant adverse effects associated with many of the prophylactic medications, pharmacologic prophylaxis is often reserved until headache frequency or intensity is great enough to have an influence on productivity and have a significant impact on quality of life, especially for female patients in child-bearing years. In light of the evidence supporting the potential significance of hyperalgesic priming in the process of headache transformation and that analgesic rebound, when present, reduces the efficacy of prophylactic medications [66] , the earlier implementation of prophylactic treatment might be reasonable to consider in patients with a strong family history of headache.
Potentially, the control of the priming cascade may provide an opportunity for reducing the incidence of CDH. Intuitively, treatment options that target the mechanisms involved in LTP and hyperalgesic priming may have a reasonable chance of preventing headache transformation. These options are best provided with a multidisciplinary approach and include (1) non-pharmacologic, physical, and cognitive modalities to reduce stress and headache intensity and duration [75, 79] , (2) the recognition and the avoidance of the modifiable triggers that increase the likelihood of reaching headache threshold, (3) the early initiation and rotation of aggressive, short duration, abortive treatments with pharmacologic agents that are less likely to produce analgesic rebound [80] , and (4) the prudent use of prophylactic agents that target the mechanisms underlying LTP and hyperalgesic priming, e.g., glutaminergic blockade, calcium channel blockade, the administration of anti-inflammatory cytokines, activators of adenosine monophosphate-activated protein kinase (AMPK) [81] [82] [83] [84] [85] , and modulators of fragile X mental retardation protein [86] and cytoplasmic polyadenylation element-binding protein (CPEB) [87] . In our current armamentarium agents that include sodium and calcium channel blockers and modulators, e.g., verapamil, gabapentin, pregabalin [6••] , the blockers of glutamate and NMDA receptors, e.g., memantine, ketamine [88] , or medications that possess a broad spectrum of actions that may affect several sites, e.g., topiramate and zonisamide [89] , may be reasonable treatment options [6••, 28, 90, 91] . Future treatments may include selective modulators of the priming cascade related to PKC and glial activation [30, 43, 92] .
When attempts to block or impede conditioned learning (LTP and hyperalgesic priming) are unsuccessful or adversely compromise their beneficial role in cognition through the use of methods designed to control the steps of the priming cascade, it may be helpful to Breturn to the basics^and approach the problem from another point of view and seek methods that selectively augment those mechanisms that reverse or limit the effects of aversive stimulation. The body responds to repetitive stimulation either positively by strengthening the protective behavior to embrace positive or avoid negative stimuli or negatively by suppressing responses to distracting and inconsequential stimulation [40, 43, 70] . Although methods for reversing hyperalgesic priming are limited and treatment options do not appear to be on the horizon, the mechanisms involved in long-term depression (LTD), habituation, and extinction, therefore, may provide important clues to potentially beneficial methods for preventing or managing the deleterious effects of chronicity [93] [94] [95] . Habituation occurs as a result of repetitive, low-frequency, homosynaptic stimulation that results in a reduction in field potentials and a decrease in primary afferent neurotransmitter release [40, 43] . The process results in an adaptation to a non-threatening stimulus and a reduction of the perception and behavioral response to that stimulus. The mechanisms that underlie habituation provide the body with a means to automatically limit perception and behavioral response when the stimuli are neutral and have no effect on survival. The conscious perception of regular patterns of stimulation, e.g., heartbeat, pulse, temperature, and clothing, changes respiration, that when normal and nonthreatening, with time, is unconditionally established as background to which new patterns are compared and suppressed. When the stimuli vary significantly from background, they are elevated to a level of consciousness, perceived, assessed, and acted upon accordingly. Habituation is similar to and may employ similar mechanisms to those underlying conditional and unconditional learning. Thus, the tools and mechanisms associated with habituation and extinction of conditional learning may be useful in managing chronic pain and CDH [93] [94] [95] . The consistent presentation of a persistent alternative, non-threatening and distracting stimulus at the time of an unconditional stimulus may lead to the extinction of the priming trigger and potential blocking, if not reversing, of the priming process [76] . The mechanisms involved in adapting to sensory overload may explain the continued interest in the possible use of acupuncture, guided imagery, and virtual imaging for treating many painful conditions [96, 97] .
Conclusion
The etiology and pathophysiology of the development of chronic daily headache remains unknown, but similarities exist between the development of chronic pain conditions and the transformation from episodic to chronic headache. Early diagnosis and the initiation of optimum management for episodic headaches may significantly reduce the incidence and prevalence of chronic daily headache. While current treatment options provide some opportunities for improving quality of life for some, once the pattern of headache becomes chronic, it is difficult, if not impossible to reverse. The process of transformation from episodic to chronic headaches is not dissimilar to the events that occur in the development of chronicity of painful conditions that occur in other areas of the body. Thus, it is likely that studies designed to discover ways of modulating the mechanisms associated with long-term potentiation, hyperalgesic priming, habituation, and extinction of classical conditioning that focus more on preventing than managing intractable conditions may hold the key to success.
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